31
Participants
Start Date
October 31, 2011
Primary Completion Date
January 31, 2012
Study Completion Date
February 29, 2012
BCI-838
BCI-838 100 mg and 300 mg or matching placebo administered as single oral doses under fasted conditions in a sequential design
BCI-838
BCI-838 administered as a single 30 mg oral dose or matching placebo under fasted and fed conditions in a crossover design
BCI-1038, BCI-1206 & BCI-1283
Three new pro-drugs administered as a 1 mg single oral doses under fasted conditions in a sequential design
BCI-838
BCI-838 900 mg or matching placebo administered as a single oral dose under fasted conditions
PRA International, Zuidlaren
Lead Sponsor
BrainCells Inc.
INDUSTRY